Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Surface Oncology Inc Stock Research

SURF

Market Closed
Watchlist

SURF Stock Price

SURF RSI Chart

SURF Valuation

Market Cap

65.0M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

1.97

Price/Free Cashflow

-0.77

SURF Price/Sales (Trailing)

SURF Profitability

Return on Equity

-118.06%

Return on Assets

-65.34%

Free Cashflow Yield

-129.16%

SURF Fundamentals

SURF Revenue

Revenue Y/Y

-100%

SURF Earnings

Earnings (TTM)

-92.5M

Earnings Y/Y

-11.82%

Earnings Q/Q

-42.81%

Price Action

Last 7 days

12.5%

Last 30 days

21.5%

Last 90 days

41.0%

Trailing 12 Months

-16.9%

SURF Financial Health

Current Ratio

7.27

SURF Investor Care

Shares Dilution (1Y)

11.12%

Diluted EPS (TTM)

-1.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SURF

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-08
GRAYZEL DAVID S.
back to issuer
-
-
-2,945,450
-
2023-09-08
ROSS ROBERT W.
back to issuer
-
-
-83,193
chief executive officer
2023-09-08
ONEILL ALISON
back to issuer
-
-
-56,686
chief medical officer
2023-09-08
Goater Jeff
back to issuer
-
-
-129,222
-
2023-09-08
FEES JESSICA
back to issuer
-
-
-101,915
chief financial officer
2023-09-08
RATH HENRY C.
back to issuer
-
-
-44,971
chief business officer
2023-09-08
Adams Chandra
back to issuer
-
-
-23,884
deputy gc
2023-09-08
Palombella Vito J.
back to issuer
-
-
-87,212
chief scientific officer
2023-09-08
Sigal Charles Elliott
back to issuer
-
-
-45,453
-
2023-08-01
Adams Chandra
sold
-3,666
0.94
-3,901
deputy gc

1–10 of 50

Which funds bought or sold SURF recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
sold off
-100
-20,000
-
-%
2023-08-21
OSAIC HOLDINGS, INC.
unchanged
-
1,816
9,104
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
1.85
162
765
-%
2023-08-15
Cornerstone Planning Group LLC
new
-
217
217
-%
2023-08-15
Formidable Asset Management, LLC
unchanged
-
2,000
13,000
-%
2023-08-15
Ground Swell Capital, LLC
new
-
17,662
17,662
0.02%
2023-08-15
GOLDMAN SACHS GROUP INC
sold off
-100
-442,738
-
-%
2023-08-14
MACQUARIE GROUP LTD
unchanged
-
59,000
304,000
-%
2023-08-14
FEDERATED HERMES, INC.
unchanged
-
451
2,294
-%
2023-08-14
TWO SIGMA ADVISERS, LP
reduced
-25.57
-1,795
22,523
-%

1–10 of 48

Latest Funds Activity

Are funds buying SURF calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SURF
No. of Funds

Schedule 13G FIlings of Surface Oncology

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 20, 2023
adar1 partners, lp
5.24%
3,183,242
SC 13G
Feb 13, 2023
ecor1 capital, llc
6.5%
3,924,713
SC 13G/A
Jan 31, 2023
atlas venture fund ix, l.p.
4.87%
2,945,453
SC 13G/A
May 09, 2022
blackrock inc.
4.6%
2,502,271
SC 13G
Mar 14, 2022
ecor1 capital, llc
9.9%
4,653,000
SC 13G
Feb 10, 2022
eli lilly & co
3.5%
1,593,997
SC 13G/A
Feb 09, 2022
ark investment management llc
11.54%
5,326,127
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 04, 2022
blackrock inc.
5.6%
2,562,685
SC 13G
Jan 25, 2022
atlas venture fund ix, l.p.
6.38%
2,945,453
SC 13G/A

Recent SEC filings of Surface Oncology

View All Filings
Date Filed Form Type Document
Sep 18, 2023
15-12G
15-12G
Sep 12, 2023
EFFECT
EFFECT
Sep 12, 2023
EFFECT
EFFECT
Sep 08, 2023
S-8 POS
Employee Benefits Plan
Sep 08, 2023
S-8 POS
Employee Benefits Plan
Sep 08, 2023
S-8 POS
Employee Benefits Plan
Sep 08, 2023
POS AM
POS AM
Sep 08, 2023
POS AM
POS AM
Sep 08, 2023
8-K
Current Report
Sep 08, 2023
4
Insider Trading

Peers (Alternatives to Surface Oncology)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.9B
26.6B
4.94% 20.46%
18.04
5.41
0.75% 21.34%
94.2B
27.4B
-1.73% 23.33%
17.17
3.44
-0.48% 32.56%
37.4B
10.7B
-12.34% -18.02%
30.97
3.51
-53.67% -91.41%
37.3B
10.0B
-2.41% 31.83%
14.01
3.74
-6.23% 29.40%
MID-CAP
11.2B
1.7B
6.64% 14.01%
63.44
6.69
29.01% 1345.90%
4.3B
-
-10.44% 191.13%
-7.34
48.33
54.84% -12.96%
2.9B
-
-7.08% -17.64%
-22.89
37.44
122.90% 54.78%
1.8B
80.2M
1.68% -49.31%
-5.62
22.95
42.17% -39.82%
SMALL-CAP
1.4B
121.2M
-15.01% -21.70%
-4.98
11.8
-70.36% -531.73%
941.3M
15.3M
-22.34% -0.87%
-5.18
61.48
1090.59% -36.57%
670.5M
1.6B
-11.68% -62.32%
-1.14
0.42
23.74% 60.24%
199.0M
-
-23.19% -90.40%
-0.94
1.45
116.83% 16.61%
118.0M
-
-12.12% -85.84%
-0.59
0.49
113.96% -15.19%
107.9M
2.1M
-9.82% -66.03%
-1.07
52.51
487.70% -8.66%
3.7M
-
-11.16% -96.28%
-0.05
3.21
- -129.46%

Surface Oncology News

Yahoo Finance
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences.
Yahoo Finance,
27 days ago
GlobeNewswire
GlobeNewswire
Penny Stocks

Returns for SURF

Cumulative Returns on SURF

-35.5%


5-Year Cumulative Returns

-46.7%


3-Year Cumulative Returns

Risks for SURF

What is the probability of a big loss on SURF?

100%


Probability that Surface Oncology stock will be more than 20% underwater in next one year

100%


Probability that Surface Oncology stock will be more than 30% underwater in next one year.

100%


Probability that Surface Oncology stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SURF drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Surface Oncology was unfortunately bought at previous high price.

Drawdowns

Financials for Surface Oncology

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q1
Revenue-100.0%-30,000,00023,171,75016,343,5009,515,2502,687,00033,555,75064,424,50095,293,250126,162,000----------56,649,000
Operating Expenses-2.7%89,386,00091,869,00094,213,00091,199,00085,678,00078,700,00074,772,00069,246,00064,686,00064,576,00061,747,00065,289,00069,399,00072,726,00071,300,00073,160,00073,518,00068,568,00072,337,00069,329,00063,042,000
  S&GA Expenses6.0%26,362,00024,866,00026,175,00026,018,00026,026,00025,128,00026,794,00025,851,00024,412,00023,558,00019,800,00019,880,00020,302,00020,608,00020,318,00019,311,00017,807,00016,076,00014,084,00014,758,00012,849,000
  R&D Expenses-10.8%59,790,00067,003,00068,038,00065,181,00059,652,00053,572,00047,978,00043,395,00040,274,00041,018,00041,947,00045,409,00049,097,00052,118,00050,982,00053,849,00055,711,00052,492,00058,253,00054,571,00050,193,000
EBITDA-----74,506,000-74,773,000-74,370,000--62,700,00062,068,000-50,832,000-52,256,000-52,523,666-53,004,000-4,908,000-5,027,000-5,141,000----
EBITDA Margin-----27.73-27.83-27.68--0.500.49-0.90-0.92-0.93-0.94-0.09-0.09-0.09----
Interest Expenses83.4%5,771,0003,146,0002,929,0002,521,0002,204,0002,546,0002,479,0003,527,0003,538,0002,855,0002,381,000912,000646,667145,000-------
Earnings Before Taxes--------------------2,482,6661,728,00014,318,667
EBT Margin-----29.21-29.21-29.21--0.470.47-0.97-0.97-0.97-0.97-0.12-0.12-0.12----
Net Income-45.5%-92,505,000-63,586,000-66,304,000-62,957,000-56,725,000-78,485,00012,913,00017,032,00021,206,00059,337,000-23,965,000-25,069,000-28,020,000-54,789,000-43,570,000-43,914,000-42,008,000-6,597,000-17,635,000-14,818,000-5,539,000
Net Income Margin100.0%--2.12-2.20-23.43-21.11-29.210.380.260.170.47-0.42-0.44-0.49--------
Free Cashflow100.0%--60,049,000-53,928,000-50,352,000-67,102,000-62,464,00025,749,00030,796,00026,590,00029,954,000-55,803,000-60,203,000-58,093,000-61,678,000-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-51.8%66.00137160182194218191189206215217145155131132139155171174186202
  Current Assets-43.5%61.0010712915016218415715517117918110811893.00108114130145165178194
    Cash Equivalents-48.8%15.0029.0051.0065.0075.0066.0056.0061.0083.0010117599.0093.0056.0047.0039.0038.0041.0083.0042.0051.00
  Net PPE-44.6%2.005.005.005.005.005.006.006.006.006.007.007.006.007.007.008.008.008.008.007.007.00
Liabilities-72.5%17.0061.0067.0069.0068.0071.0072.0057.0057.0056.0061.0059.0057.0050.0075.0070.0071.0070.0071.0080.0080.00
  Current Liabilities14.1%17.0015.0016.0018.0020.0020.0020.0016.0019.0015.0018.0014.0011.0013.0019.0016.0015.0013.0027.0028.0025.00
Shareholder's Equity-35.1%49.0076.0093.0011312614711913114815915686.0098.0082.0057.0069.0084.00100103106122
  Retained Earnings-12.6%-252-224-204-183-159-134-140-116-96.80-77.82-62.26-129-113-99.02-121-105-88.76-71.00-66.81-62.07-44.85
  Additional Paid-In Capital0.4%302300299297287282260248245237218216211180178174173171170168167
Shares Outstanding0.0%61.0061.0061.0061.0055.0049.0047.0045.0044.0042.0041.0040.0033.0028.0028.0028.0028.0028.0028.0017.0022.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-40.6%-83,581-59,425-59,552-53,655-50,086-66,947-62,34425,82230,81626,61029,997-55,650-59,779-57,408-60,140-60,744-58,497-62,541-13,222-13,746-11,064
  Share Based Compensation-12.7%6,1177,0047,2237,5477,8258,0318,5468,6558,5748,2957,7657,3586,9616,4465,9915,6685,3165,3215,2174,6686,258
Cashflow From Investing252.7%41,35311,72622,7575,471-3,032-16,153-99,252-86,512-61,981-37,15458,30770,13568,93865,29416,96557,13644,931-65,806-36,584-85,139-85,846
Cashflow From Financing-275.5%-19,34911,02431,66052,43244,60748,23142,50022,07221,37554,65140,08246,85546,6127,6177,415539552110,485110,376109,270109,031

SURF Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Statement of Comprehensive Income [Abstract]    
License-related revenue$ 0$ 0$ 0$ 30,000
Operating expenses:    
Research and development13,83118,19827,60834,822
General and administrative8,5766,42614,46012,967
Restructuring charges3,23403,2340
Total operating expenses25,64124,62445,30247,789
Loss from operations(25,641)(24,624)(45,302)(17,789)
Interest expense(3,108)(733)(4,040)(1,415)
Other income (expense), net5571441,409190
Net loss$ (28,192)$ (25,213)$ (47,933)$ (19,014)
Net loss per share — basic (in dollars per share)$ (0.46)$ (0.46)$ (0.79)$ (0.37)
Net loss per share — diluted (in dollars per share)$ (0.46)$ (0.46)$ (0.79)$ (0.37)
Weighted average common shares outstanding— basic (in shares)60,717,89954,654,82260,673,19551,647,148
Weighted average common shares outstanding— diluted (in shares)60,717,89954,654,82260,673,19551,647,148
Comprehensive loss:    
Net loss$ (28,192)$ (25,213)$ (47,933)$ (19,014)
Other comprehensive loss:    
Unrealized gain (loss) on marketable securities, net of tax of $0348(259)794(949)
Comprehensive loss$ (27,844)$ (25,472)$ (47,139)$ (19,963)

SURF Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 14,842$ 50,910
Marketable securities41,41673,913
Prepaid expenses and other current assets4,3304,317
Total current assets60,588129,140
Property and equipment, net2,4994,866
Operating lease right-of-use asset2,91924,307
Restricted cash01,595
Other assets02
Total assets66,006159,910
Current liabilities:  
Accounts payable609256
Accrued expenses and other current liabilities6,73110,214
Operating lease liability9,4885,790
Total current liabilities16,82816,260
Operating lease liability, non-current024,662
Convertible note payable, non-current025,585
Total liabilities16,82866,507
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized    at June 30, 2023 and December 31, 2022; no shares    issued and outstanding at June 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 150,000,000 shares    authorized at June 30, 2023 and December 31, 2022, respectively;    60,730,274 and 60,578,956 shares issued and outstanding at June 30, 2023    and December 31, 2022, respectively66
Additional paid-in capital301,655298,741
Accumulated other comprehensive loss(221)(1,015)
Accumulated deficit(252,262)(204,329)
Total stockholders’ equity49,17893,403
Total liabilities and stockholders’ equity$ 66,006$ 159,910
Robert W. Ross
70
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.